An interventional study of D-QUIT App and Questionnaires in Nicotine E-Cigarette Use, Vaping and Vaping Cessation, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 29 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Vaping by University of California, San Francisco — 4 open to participants now, 4 under way, none of them phase 3. Vaping · University of California, San Francisco.
Among the 17 studies in Vaping by University of California, San Francisco, this one is the 5th largest by planned enrollment, is the only one that started in 2027, is one of 13 with no phase, and was the 17th registered.
403 studies on the registry are indexed under Vaping; 96 are open to participants now.
Browse Vaping studies →4 of the 17 studies in Vaping by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 13+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 21–65 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 21–65 · Healthy volunteers
By country, each count listing its studies:
Of the 64 Vaping studies recruiting now, 32 (50%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 29 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 50 is below the median of 80 across 323 interventional studies indexed under Vaping.
Median enrollment 27 across the 17 interventional studies. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 371 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 203 (76%) have results posted.
2 of the studies in Vaping by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07540780University of California, San FranciscoSocial Media Support Groups for Adolescent Vaping Cessation | 2027-01-31 |
| NCT05962229University of California, San FranciscoComparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Vaping by University of California, San Francisco, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A pilot study evaluates the feasibility and acceptability of D-QUIT, an AI-powered smartphone app providing personalized behavioral support for nicotine and cannabis vaping cessation among young adults.
Primary Objective:
I. To evaluate the feasibility and acceptability of D-QUIT, a smartphone app enhanced by an AI chatbot for vaping cessation.
Secondary Objective:
I. To assess intervention engagement and preliminary vaping cessation outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will use the D-QUIT smartphone app for 6 weeks to support their goals for quitting or reducing nicotine and cannabis vaping. During the 2 weeks before their nicotine vaping quit date, participants will receive app notifications to help identify vaping patterns and triggers, set goals, and learn coping skills. Beginning on the quit date, participants will receive tailored messages for 4 weeks with tips for managing withdrawal and support based on their vaping goals. Participants will also be encouraged to interact with the chatbot for 5-15 minutes daily and complete brief morning and end-of-day check-ins about vaping, cravings, mood, and withdrawal symptoms. At the end of the intervention, participants will complete a survey, and a subset will be invited to an interview to provide feedback on D-QUIT.
Behavioral: D-QUIT App · Other: Questionnaires
A Smartphone App Enhanced by AI Chatbot Delivered Remotely via Mobile Phone
Feasibility and Acceptability Measures administered at the end of 6-week intervention.
Feasibility of the D-QUIT Smartphone App
Feasibility will be assessed using the 4-item Feasibility of Intervention Measure (FIM). Each item is rated on a 5-point scale from 1 (Completely disagree) to 5 (Completely agree). Higher item scores indicate greater perceived feasibility of the intervention. Descriptive data will be reported.
Time frame: At Week 6
Acceptability of the D-QUIT Smartphone App
Acceptability will be assessed using the 4-item Acceptability of Intervention Measure (AIM). Each item is rated on a 5-point scale from 1 (Completely disagree) to 5 (Completely agree). Higher item scores indicate greater acceptability of the intervention. Descriptive data will be reported.
Time frame: At Week 6
Intervention Engagement
Intervention engagement will be assessed using participants' duration of D-QUIT use (0-6 weeks) and the frequency of chatbot use during the intervention. Descriptive data will be reported.
Time frame: At Week 6
Preliminary Vaping-Cessation Outcomes
Preliminary vaping-cessation outcomes will be assessed using self-reported measures of nicotine and cannabis vaping, including the number of days vaped in the past 30 days or the number of quit attempts since starting D-QUIT. Use of other nicotine/tobacco and cannabis products will also be assessed. Descriptive data will be reported.
Time frame: At Week 6
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jul 2028, 18 months later.
Of 184 non-industry interventional studies with no phase under Vaping, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 18 months is close to that.
Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →